Last Friday at the British Consulate in Cambridge, three innovators described emerging technologies that are changing how and where healthcare is delivered–and the challenges of bringing those  technologies to market.

Jacqueline Thong, CEO and Co-Founder of Ubiqi Health, in Boston,   is developing mobile tools to track and use data on patient compliance.  Bringing Ubiqui’s  first product–which measures the impact of life style changes on  migraine headache sufferers, to market–has been slow,  Thong said, but over the course of 18 months, her company  acquired 15 thousand users,  developed a reporting system, and assessed  results.  While, originally, her company had expected reports on impact to be shared only with providers, her team found that patients were interested in knowing their results–and that when provided access,  their compliance and positive outcomes increased.

Thong  emphasized the emphasized the importance of measuring impact and showcasing findings to potential partners.  Merck and the Joslin Diabetes Center are now interested in testing the device with their patients, as are other pharma companies, payor organizations interested in cutting costs, and physicians, Thong said.

Mira Sahney, General Manger, Gynecology Business at  Smith & Nephew  Endoscopy, is building a women’s health division at the company.  She is in the process of commercializing a minimally invasive surgical tool for use in doctors offices that removes fibroids and polyps which have long been a leading cause of  hysterectomies. While, in Europe, use of the minimally-invasive procedure (hysteroscopy) in doctors’ offices  is  encouraged and financially incentivized,  introducing it to the US market has been challenging, she said.

Medicare reimburses differently depending on the location but in any case, will not pay for the procedure if performed in the doctor’s office. Getting FDA approval for a new product can take years, she said. “You need promoters.” “What is more, the American College of Gynecology  is slow and conservative;  private insurers can  see and implement the benefits but are moving slowly.  Anyone seeking to market  a paradigm-shifting device must be  prepared to work at the “micro” level, she emphasized. “commercialization is completely different in every market.”

Peter Vicars, President and CEO of VGo Communications, in Nashua,  NH,  emphasized the importance of focus in introducing a new product. His company has developed a “telepresence robot” that can moved around a space to provide  video-like audiovisual information  — by someone at a computer many miles away.  Vgo robots can be used for security, advertising and in homes and schools, Vicars said.

For example, a child with immune deficiency could not go to school, but by sending a robot in his place, he could observe the goings on and interact with students and classmates.

Robots are being  used by families to communicate with patients in nursing homes–and are also  used by health providers to monitor patients.  For example,  at a children’s hospital found that they had a 50% readmission rate–not because the doctors had done anything wrong but because parents tended to panic and bring their kids back to the hospital in case of the slightest worry.  To cut back on expensive readmissions,  one of the doctor now sends a Vgo robot home with every patient. He can then see what’s going on, thus making a virtual house call.

The possibilities seem endless, Vicars said, but it’s crucial to focus in order to determine “is there an opportunity and can you capitalize on it?”

The program was developed and moderated  by Tanya Kanigan, Founder of  Proof of Market,  which helps engineering driven companies identify and develop opportunities for their technologies and services in life science and healthcare markets.

—Anita M. Harris

You don’t need to be a geek to get into some of the newest technology for keeping track of your health. I was blown away when I heard about pill bottle caps that will tell  you (or your doctor or your caretakers)  if you’ve forgotten to take your meds…a kazoo that measures the chemistry of the air from your lungs…and a telephone that can assess whether you’re depressed–from the tones of your voice.

These gizmos are the brainchildren of David Rose, an entrepreneur who is now the CEO of Vitality, Inc., in Cambridge.  Rose has also invented bathroom scales that can show whether you’ve lost or gained weight, an umbrella that can sense whether it’s going to rain, and objects that assess air quality.

Rose was one of four panelists who spoke last week at a program sponsored by the Medical Development Group about some astounding new health gadgets, most of which are actually on the market. (MDG is a Boston area organization for individuals involved in the medical device and technology industries). 

Rose focused on the above-mentioned pill bottle “Glo-Caps”, which “sense”  when a patient takes a medication, and, via a wireless Internet connection, show health care professionals, patients or caregivers whether reminders are needed.  

The caps light up, play a melody, and even ring a home phone to remind patients to take their pills.  The caps can send weekly emails to remote caregivers, create accountability with doctors through an adherence report, and automatically refill prescriptions. 

Glo-Caps are not currently available for purchase by individuals, but they are being used by patients enrolled in programs sponsored by certain health insurers and pharmacies.

Panelist Ben Rubin, Co-Founder and Chief Technology officer of Zeo, in Newton, MA, described Zeo’s novel  headset and device that monitor an individual’s REM sleep and factors influencing sleep patterns.  Knowing how well you sleep is important because sleep is closely tied to health conditions like obesity, depression, diabetes and the like, Rubin said. “If you measure it, you can manage it.” 

Zeo’s sleep devices, which cost $250,  connect to  an Internet site. For an additional $100, Zeo provides email advice coaching to help individuals improve their “sleep hygiene.” 

There’s also a  Smart Phone application designed to promote better sleep:  using the Ap, you put your phone under your pillow to measure your movement (and restlessness) during sleep.

Panelists also described glucose monitors that send data to doctors via patients’ Smart Phones and Nike running shoes that measure your steps. At one point, Rose pulled out a keychain that tells him whether he’s met his daily walking goals and whether he’s on track (ha ha) to meet his monthly goals.

Also mentioned  were Internet tools such as a Google Ap to measure flu trends; Healthmedia, through which Johnson & Johnson provides digital coaching for managing stress and chronic disease, Philips Direct, which provides live coaching over email, and various “calorie and other body monitors through which individuals can receive online coaching through gyms.

All of these devices fall under a category moderator David Barash, MD, CEO of Concord [MA] Health Strategies calls “local health monitoring” –meaning that the devices can be used by patients or consumers almost anywhere–rather than just at home or in a hospital,  doctor’s office or lab.

 According to a recent review by my client, Scientia Advisors, “remote health monitoring” devices are the fastest growing category in a booming home health care market. 

The devices are growing in popularity in sync with an aging population, increasing chronic disease, and new Internet technologies, Barash said.

Panelist Frank McGillin, Vice President of Global Marketing for Philips Healthcare, which markets a variety of home monitoring devices, said  remote monitoring  will become increasing important in light of growing health care costs.

Gillin cited government statistics showing that  health care current accounts for 17.6 percent of the  gross domestic product in the US, and that by 2050, half of the population in the developed world will be chronically ill—making traditional medical care  fiscally overwhelming. 

Devorah Klein, PhD, a principal at Continuum, in Newton, MA, who designs devices and evaluates patient adherence to therapy regimes for diabetes, asthma, arthritis, multiple sclerosis and erectile dysfunction, emphasized that  simple designs are key because “many patients are not all that interested” in learning to use devices.

And Barash pointed out that while many consumers may be intrigued by these gizmos, doctors have been slow to embrace them.

 For one thing, with a dearth of clinical trials to assess devices’ effectiveness, insurers are reluctant to reimburse doctors for evaluating the data thus compiled.

For another,  it’s not clear how doctors can manage or assess  potentially large amounts of additional data, or  how data collected for individual conditions can be assessed in relation to data collected elsewhere for other, possibly related, conditions.

–Anita M. Harris

New Cambridge Observer is published by the Harris Communications Group, a  writing  and public relations firm in Cambridge, MA.  All rights reserved.